Guardant Health, Inc. (GH) Stock Price & Analysis

Guardant Health, Inc. (GH) closed at USD 162.94 on Thursday, October 22, 2026, down 2.23% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 166.66; the Oct 22, 2026 session ranged USD 158.68–167.25 on volume of 1,770,605 shares. Market capitalization is $21.87B, with a 52-week range of USD 66.59–191.05 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:14 UTC.

Also available as compact Markdown for AI agents: nexqual.com/GH.md

Key facts (GH)

• Last four reported quarters (through Jun 30, 2026): revenue $1.18B, net income -$453M (-38.3% margin), free cash flow -$241M (SEC filings).
• 1 of 80 tracked superinvestors hold GH (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
• Analysts: Buy (mean 1.96 on a 1–5 scale) (26 analysts), mean target USD 201.64 (range 105–240).
• Total return with dividends: 1Y +134.9% vs S&P 500 +14.9%; 5Y +49.0% vs S&P 500 +80.3%.
• Next earnings: 2026-11-05, EPS estimate USD -0.31, revenue estimate $351M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GH)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (GH)

P/S 18.5x · EV/Sales 18.9x · FCF yield -1.10% · Earnings yield -2.07% · Buyback yield (TTM) 0.00% · Net debt $449M · EV $22.3B

Superinvestors (SEC 13F-HR, Q2 2026) (GH)

1 of 80 tracked investors hold GH. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Analysts (GH)

Consensus Buy (mean 1.96 on a 1–5 scale), 26 analysts; mean target USD 201.64 (low 105, high 240).

Rating changes, last 120 days:

Total return (dividends reinvested) (GH)

GH revenue by product line (quarter ended Jun 30, 2026)

GH revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

GH suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 19, 2026.

GH customer concentration

In the period ended Jun 30, 2026, a single direct customer accounted for 27% of revenue, per the company's 10-Q filed Jul 30, 2026. The company does not name it.

GH company outlook (results filed Jul 30, 2026)

• “Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.34 to $1.36 billion, representing growth of 36% to 38% PALO ALTO, Calif.”

Analysts expect $350.6M for the current quarter, 74.0% below the midpoint of the company's guidance ($1.35B).

Quoted word-for-word from the SEC 8-K results press release.

GH analyst estimates and revisions

GH options: expected move

Options price a move of about ±16.3% (±$26.60) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±9.4% on average.

30-day implied volatility 70.2% vs 49.3% realized over the last 30 trading days. Put/call ratio (volume) 1.64. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:14 UTC)

Technical Analysis (GH)

Nexqual's technical model rates GH "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:14 UTC.

Analyst Ratings (GH)

Wall Street analysts rate GH "Buy" based on 26 analysts, with a mean price target of USD 201.64 (range USD 105–240), per Nexqual as of October 23, 2026 at 09:14 UTC.

Earnings (GH)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:14 UTC.

Financials & Fundamentals (GH)

Source: Nexqual, October 23, 2026 at 09:14 UTC.

Financial Health Score (GH)

Nexqual rates Guardant Health, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:14 UTC.

Ownership (GH)

Source: Nexqual, October 23, 2026 at 09:14 UTC.

Leadership (GH)

Guardant Health, Inc. is led by Helmy Eltoukhy, Co-Founder, Co-CEO & Chairman, per Nexqual as of October 23, 2026 at 09:14 UTC.

Major Backers & Investors (GH)

Notable institutional backers of Guardant Health, Inc. include Price (T.Rowe) Associates Inc, FMR, LLC, Invesco, according to Nexqual as of October 23, 2026 at 09:14 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:14 UTC.

From Guardant Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• Building on Guardant Reveal's proven performance in MRD detection, the expanded offering leverages our proprietary epigenomic technology powered by the Smart Platform to predict therapy response across all therapy classes, including immunotherapy and chemotherapy, which most patients with advanced-stage cancer receive at some point during their treatment.
• Our proprietary Smart Platform delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic.
• Our product portfolio is now powered by our Smart Platform, which utilizes methylation technology with genomic, epigenomic, and RNA-based data, to unlock multi-modal biology with proprietary chemistry, advanced algorithms and our InfinityAI learning engine.
• We believe our Guardant360 CDx test was the first comprehensive liquid biopsy test approved by the FDA, and is the market leading comprehensive liquid biopsy test, based on the number of tests ordered.

Partnerships

• In June 2022, we signed a strategic partnership agreement with Adicon Holdings Limited, or Adicon, a leading independent clinical laboratory company based in China, and in December 2023, the blood-based cancer testing services based on our digital sequencing platform became available at Adicon's testing facility, which offers our industry-leading comprehensive genomic profiling tests to biopharmaceutical companies to advance clinical research and the development of new cancer therapies in China.
• In September 2014, we entered into a supply agreement with Illumina, Inc., or Illumina, for Illumina to provide products and services that can be used for certain research and clinical activities, including certain sequencers, reagents, and other consumables for use with the Illumina sequencers, as well as service contracts for the maintenance and repair of the sequencers.

Legal & Regulatory Risks (Item 1A, quoted)

• Changes to FDA Regulation of Companion Diagnostics Could Adversely Affect Our Business and Competitive Position
• The FDA has proposed reclassifying certain companion diagnostic tests from Class III devices requiring PMA to Class II devices subject to special controls and the 510(k) process. Although the proposal is not final and its scope and implementation remain uncertain, any change to the regulatory framework for companion diagnostics could materially affect our business.
• Our "research use only" and "investigational use only" products could become subject to more onerous regulation by the FDA or other regulatory agencies in the future, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.
• Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales of our products and have a material adverse effect on our reputation, business, results of operations and financial condition.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:14 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt